Eurofins Technologies announces the launch of its GSD NovaType III SARS-CoV-2 RT-PCR assay, developed for the rapid detection of SARS-CoV-2 variants of concern including B.1.617 (“India”), B.1.427/B.1.429 (“California/USA”), B.1.351 (“South Africa”) or P.1 (“Brazil”). The assay facilitates the identification of the relevant mutations E484Q, E484K and L452R in one reaction combined with the simultaneous discrimination from the S gene E484 wildtype variant. These mutations have been associated with reports of potential decreased efficacy of certain vaccines and an increase in the transmissibility of the virus.
Eurofins Technologies continues to develop a range of diagnostic solutions for COVID-19, particularly in response to the threat of emerging mutations. Today, we announce the launch of two new products: GSD NovaPrime® Plus SARS-CoV-2, a PCR test which can identify, in one reaction, key variants of concern including the UK variant; and GSD NovaType Select L452R (RUO) the first test of its type able to identify critical variants such as the Indian, USA and Californian variants. Eurofins Technologies will continue to invest in R&D to develop further reliable, high-quality testing solutions for the SARS-CoV-2 virus and its variants.
Earlier this year, we launched our new and improved Lateral Flow Device product line for allergen detection in foodstuffs and environmental samples. These products quickly detect allergens that must be labeled on packaged food products.
Our customers were pleased to discover the new devices, as this easy-to-use and quick method requires only a few minutes of incubation time, with low detection limits.
For the efficient monitoring of aflatoxin contamination, it is necessary to apply analytical kits capable to detect all the four aflatoxins B1, B2, G1 and G2, in an accurate and preferably fast manner.
H2AFLA is a new rapid ELISA kit for the detection of total aflatoxins B and G in different types of matrices. The kit is using an antibody with high cross-reactivity for the four forms of aflatoxins: measured in the absence of matrix at 50% inhibition, the cross-reactivity was 100% for aflatoxin B1, 92% for B2, 86% for G1 and 76% for G2.
Eurofins Technologies announces the launch of its GSD NovaType II, its upgraded RT-PCR kit for the identification of mutations associated with SARS-CoV-2 variants of concern.
The first GSD NovaType RT-PCR kit was launched in February 2021 and quickly supported health authorities in the detection of variants in more than 100,000 COVID-19 positive patients across Europe. The new GSD NovaType II kit can now detect the N501Y and E484K mutations common to most VOC (Variants Of Concern) and the K417N mutation (specific to B.1.351 first identified in South Africa), with high sensitivity.
Eurofins adds today virus variant monitoring capabilities to its commercially available SARS-CoV-2 stand-alone test kit portfolio. This new solution is also part of the Eurofins Covid-19 Sentinel™ and the SAFER@WORK™ program which provide an early warning of the presence of SARS-CoV-2 amongst large populations at a given site (e.g. a city, factories, education institutions, government and public service sites, nursing homes), before the virus spreads too broadly.
At those sites, wastewater and environmental surface testing, offered as part of the Eurofins COVID-19 Sentinel™ programme, can give an early indication of the presence of SARS-CoV-2 variants, therefore allowing for relevant containment measures in order to avoid an outbreak of the disease even before symptom onset, and now also identifying the involved virus variants.
Launch of the GSD NovaPrime® SARS-CoV-2 Direct RT-PCR
The GSD NovaPrime® SARS-CoV-2 Direct RT-PCR is intended for the qualitative detection of SARS-CoV-2 from human nasopharyngeal swabs, eluted directly into deionised water without an additional RNA extraction process (extraction-free).
Increase of global SARS-CoV-2 testing worldwide has posed new challenges to laboratories in nearly all countries. More than ever, there is a critical need for rapid molecular solutions to increase testing capacity, and provide accurate and faster results. Removing the RNA extraction step helps to meet this challenge, by increasing the number of laboratories that can perform these tests, allowing more tests to be performed and reducing the cost, labour, and time required to carry out very sensitive PCR tests.
Eurofins launches a new CE marked serological assay for the identification and quantification of antibodies to SARS-CoV-2. This ELISA kit can support vaccination campaigns by monitoring the antibody levels over time.
Vaccination against COVID-19 is a critical element in the fight against the pandemic. The spike protein covers the surface of the SARS-CoV-2 virus and is responsible for attachment and invasion of human cells. All currently approved vaccines use the spike protein to train the immune system to detect and neutralize this virus.
Eurofins is making new assays for the identification of B.1.1.7 (UK) and B.1.351 (South Africa)/B.1.1.248 (Brazil) variants with a one hour run time available for free to public health institutions who do not have capabilities to rapidly identify the presence of these variants.
SARS-CoV-2 belongs to a group of RNA viruses that exhibit spontaneous mutations. Some alarming variants have recently been identified including: The new lineage B.1.1.7 first identified in South England and the lineages B.1.351 and B.1.1.248 initially discovered in South Africa and Brazil, respectively. All of these variants appear to be more infective.
Next Generation Sequencing (NGS) is generally used for detecting new mutations of the virus as part of epidemiological studies. However, NGS typically takes three to five days. This is often too slow to identify carriers of the new variants so that their contacts can be isolated and tested as a matter of priority to stop the spread of these variants in regions where they are not yet prevalent.
Eurofins Technologies and Eurofins Genomics are pleased to announce the launch of two validated assays for the identification of B.1.1.7 (UK) and B.1.351 (South Africa) variants with a short turn-around time.
Emerging role of new SARS-CoV-2 mutations B.1.1.7 and B.1.351 variants
The rapid spread of SARS-CoV-2 has put the world on alert. This emerging virus belongs to a group of RNA viruses that have very high rates of spontaneous mutations, resulting in an extraordinary ability to quickly adapt to new hosts and environments. Even though multiple random mutations in the SARS-CoV-2 genome have been observed since its first emergence, recent scientific reports have identified two new SARS-CoV-2 variants which have raised special attention and are more alarming because of their concerning epidemiological features, characterized by higher infection rates and rapid replacement of prevalent virus lineages.
The new lineage B.1.1.7, which was first identified in South England, is defined by an unusually large number of 23 mutations. The lineage B.1.351 was initially identified in South Africa. Both variants show mutations in different positions of the S gene. Especially the mutation N501Y, which is found in both the UK (B.1.1.7) and the South Africa (B.1.351) virus variants, seems to increase infectivity.